Friday, 6 November 2026European Markets

CNOVA Stock 13.74% Up Today

Loading stream...

(vianews) - the market ended the session with cnova (cnv.pa) jumping 13.74% to €3.89 on tuesday while cac 40 slid 0.46% to €7,339.27.

cnova's last close was €3.42, 42.23% under its 52-week high of €5.92.

about cnova

cnova n.v. operates as an e-commerce company in france and western europe. the company offers home appliances, consumer electronics, computers, home furnishings, and leisure and personal goods through its cdiscount.com website. it also operates cdiscount voyages, a travel platform; cdiscount billetterie, a ticketing platform; cdiscount energie for home energy; cdiscount mobile for cell phone plans; cdiscount advertising, a digital marketing solution; octopia for turnkey marketplace solutions to retailers and e-merchants; and c-logistics and c chez vous for transportation and logistics services. the company was founded in 1998 and is headquartered in amsterdam, the netherlands. cnova n.v. is a subsidiary of casino, guichard-perrachon s.a.

earnings per share

as for profitability, cnova has a trailing twelve months eps of €-0.28.

revenue growth

year-on-year quarterly revenue growth declined by 29.2%, now sitting on 1.7b for the twelve trailing months.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, cnova's stock is considered to be oversold (<=20).

moving average

cnova's worth is way higher than its 50-day moving average of €3.08 and above its 200-day moving average of €3.80.

more news about cnova (cnv.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,552 source documents archived
Query this data → isubstrate.com